Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mendus B V has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, LARA, CAROLINE MONSERRAT, who is the busiest examiner for the portfolio with 1 pending case. Prosecution is limited to 1 distinct art unit. This indicates a very focused and centralized approach to the company's current active patent application, with all work handled by a single examiner.
With only one active matter and one assigned examiner, the company has a very streamlined presence at the patent office. This singular focus on the assigned art unit means that the company's current legal efforts are not diluted across multiple administrative channels. LARA, CAROLINE MONSERRAT holds total influence over the portfolio's current trajectory. Practitioners should prioritize a clear and direct communication line with this examiner to resolve any issues. Understanding the specific examination culture of this single art unit is essential for predicting the timeline and eventual outcome of the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18197670 | USE OF LEUKEMIA-DERIVED CELLS FOR ENHANCING NATURAL KILLER (NK) CELL THERAPY | LARA, CAROLINE MONSERRAT | 92d overdue |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18197670 | USE OF LEUKEMIA-DERIVED CELLS FOR ENHANCING NATURAL KILLER (NK) CELL THERAPY | LARA, CAROLINE MONSERRAT | 1633 | §103 | Non-Final OA | 92d overdue | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial